P
Description
PILA PHARMA is a Swedish clinical biotech based in Malmö, listed on Nasdaq First North Growth Market (PILA). It develops TRPV1 inhibitors as a novel treatment for obesity, type 2 diabetes and other inflammatory diseases. Its lead candidate XEN-D0501 (highly selective TRPV1 inhibitor, ex-Bayer/Xention) has completed Phase 2a trials for diabetes. In 2022 received FDA orphan drug designation for erythromelalgia.